{ "docId": "019dd923-622c-750b-8b9a-3bcd52c6e583", "docSlug": "f06b0b5d2079", "documentTitle": "Soleno Therapeutics (SLNO)", "authorId": "58_Scorpion_Capital", "authorName": "Scorpion Capital", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "short_seller", "sourceTypeLabel": "Short seller", "presentationDate": "2025-08-15 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 247, "pageCount": 415, "prevPage": 246, "nextPage": 248, "slideType": "expose_contradiction", "function": "expose_contradiction", "density": "dense", "nDataPoints": 2, "notes": "The slide uses a Q&A transcript format to build a case against the safety of the drug Vykat.", "elementsJson": [ "paragraph", "quote_block", "footnote" ], "metadataConfidence": 1, "imagePath": null, "slideHref": "/slides/019dd923-622c-750b-8b9a-3bcd52c6e583/247", "deckHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583", "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583.json", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583#slide-247", "components": [ { "bbox": null, "kind": "callout", "text": "I do know at least two families that dropped out of the Vykat study...both of their kids got diabetes...they were not pre-diabetic...that’s concerning to me...and both of them are still now struggling with controlling diabetes...people who take this drug – you now have another problem that you have to treat, that’s a bigger problem.", "attrs": null, "subkind": null, "toolName": "Visual emphasis", "toolSlug": "visual-emphasis", "confidence": null, "componentId": "019dd953-64ce-7561-b2aa-d23d41c4fbaa", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.48, "w": 0.86, "x": 0.07, "y": 0.44 }, "kind": "paragraph", "text": "Two patients in their early 20’s allegedly developed diabetes shortly after starting Vykat; still uncontrolled several years later; A: “We did talk to Soleno when they were doing their Phase 3 trial...we did see the data, and we did see the number of people who had diabetes. I do know at least two families that dropped out of the Vykat study, and both of their kids got diabetes, and they were not pre-diabetic. That’s concerning to me. And both of them are still now struggling with controlling diabetes. I think that people who take this drug —you now have another problem that you have to treat, that’s a bigger problem —” Q: “These are patients who were not pre-diabetic and then got full-blown diabetes. Is that what you said?” A: “Yep.” Q: “And how old were these patients?” A: “Early 20s.” Q: “And how long were they on the drug?” A: “I think one was on it for four months, and the other was right around the same time. Both dropped out.” Q: “So, four months. And when did the diabetes develop?” A: “I think somewhere within a couple of months of starting the drug.” Q: “And how long have they been trying to get the diabetes under control? Does it sound like they're stuck with it after being on the drug? It didn't go away after they stopped treatment?” A: “Two or three years ago, yeah.” Q: “So, two people in their 20s got diabetes after four months on drug, and they still have it a couple of years later?” A: “Yeah.” Q: “And were they obese — I get all these kids are at risk for diabetes.” A: “Sure. Just a little something. If you look at them on the street, they would not stand out as somebody who was obese. I would say slightly overweight for both of them.” – KOL in the PWS field; involved with Soleno’s clinical program", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "29058802-6010-4ec5-af11-80cb1d086e7f", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.35, "w": 0.86, "x": 0.07, "y": 0.07 }, "kind": "paragraph", "text": "Alarmingly, the KOL alleged that Soleno's data shows a diabetes signal – “we did see the data, and we did see the number of people who had diabetes.” The KOL alleged that “at least” two patients in their early 20’s developed diabetes while on the drug and dropped out; that neither was pre-diabetic nor obese; that the diabetes occurred rapidly, within a few months; that the diabetes is still uncontrolled, several years later – “I do know at least two families that dropped out of the Vykat study...both of their kids got diabetes...they were not pre-diabetic...that’s concerning to me...and both of them are still now struggling with controlling diabetes...people who take this this drug – you now have another problem that you have to treat, that’s a bigger problem.”", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "54b288ad-805b-4a56-8e95-208bc75cbffd", "frameworkName": null, "frameworkSlug": null }, { "bbox": null, "kind": "quote", "text": "“We did talk to Soleno when they were doing their Phase 3 trial...we did see the data, and we did see the number of people who had diabetes. I do know at least two families that dropped out of the Vykat study, and both of their kids got diabetes, and they were not pre-diabetic. That’s concerning to me. And both of them are still now struggling with controlling diabetes. I think that people who take this drug —you now have another problem that you have to treat, that’s a bigger problem —” — KOL in the PWS field; involved with Soleno’s clinical program", "attrs": null, "subkind": null, "toolName": "Authority citation", "toolSlug": "authority-citation", "confidence": null, "componentId": "019dd953-64ce-7561-b2aa-d6702413135b", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.02, "w": 0.25, "x": 0.07, "y": 0.95 }, "kind": "source-note", "text": "Source: Scorpion Capital consultation calls with experts", "attrs": null, "subkind": null, "toolName": null, "toolSlug": null, "confidence": null, "componentId": "b702d768-b18d-4433-84cb-2d223abe4ba8", "frameworkName": null, "frameworkSlug": null } ], "metrics": [], "tools": [], "frameworks": [ { "name": "fraud-exposure", "slug": null, "matchId": "96d4aed5-d357-4f66-8320-8d6e8625445c", "evidence": "The slide uses expert testimony to allege a hidden safety issue (diabetes) in clinical trial data.", "confidence": 0.9 } ], "arcBeats": [], "loops": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }